Napthyridine Compounds As Rock Inhibitors
    1.
    发明申请
    Napthyridine Compounds As Rock Inhibitors 审中-公开
    萘啶化合物作为岩石抑制剂

    公开(公告)号:US20080207677A1

    公开(公告)日:2008-08-28

    申请号:US11813236

    申请日:2006-01-02

    CPC分类号: C07D471/04

    摘要: The present invention relates to compounds having a naphthyridine scaffold, and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these naphthyridine derivatives together with pharmaceutically acceptable carrier, excipient and/or diluents. Said naphthyridine compounds have been identified as inhibitors of the protein kinase ROCK2, also known as Rho-kinase, and are useful for the treatment of cancers (tumor growth and metastases), erectile dysfunction, cardiovascular diseases, hypertension, angina pectoris, cerebral ischaemia, cerebral vasospasm, myocardial ischaemia, coronary vasospasm, heart failure, myocardial hypertrophy, atherosclerosis, restenosis, spinal cord injuries, neuronal degeneration, thrombotic disorders, asthma, glaucoma, inflammation, anti-viral diseases (e.g. HIV), and osteoporosis.

    摘要翻译: 本发明涉及具有萘啶支架的化合物,以及这些化合物的立体异构形式,前体药物,溶剂合物,水合物和/或药学上可接受的盐,以及含有这些萘啶衍生物中至少一种以及药学上可接受的载体,赋形剂和 /或稀释剂。 所述萘啶化合物已被鉴定为蛋白激酶ROCK2(也称为Rho-激酶)的抑制剂,可用于治疗癌症(肿瘤生长和转移),勃起功能障碍,心血管疾病,高血压,心绞痛,脑缺血, 脑血管痉挛,心肌缺血,冠状动脉血管痉挛,心力衰竭,心肌肥大,动脉粥样硬化,再狭窄,脊髓损伤,神经元变性,血栓形成障碍,哮喘,青光眼,炎症,抗病毒疾病(例如HIV)和骨质疏松症。